Reconstitution
Commercial levocarnitine injection is supplied as a sterile solution. Powder-based research formulations require formulation-specific documentation rather than an assumed reconstitution recipe.
BacScience Research Reference
L-Carnitine Reconstitution & Research Reference
L-Carnitine, also known as levocarnitine, is a naturally occurring quaternary ammonium compound involved in fatty-acid transport and mitochondrial energy metabolism. This research reference examines L-carnitine identity, clinical research, injectable formulations, diluent compatibility, concentration calculations, stability, storage, sterility, endotoxin and quality considerations.
Compound L-Carnitine / Levocarnitine
Chemical class Quaternary ammonium compound
Molecular formula C₇H₁₅NO₃
Molecular weight ≈161.20 g/mol
Research applications Energy metabolism, deficiency, renal disease
Human evidence Extensive; route and indication dependent
Common formulations Oral products and sterile levocarnitine injection
Last reviewed September 2026
L-Carnitine Reconstitution: Quick Answer
Does L-carnitine commonly require reconstitution? No. An FDA-labeled levocarnitine injection is supplied as a ready-to-use sterile solution rather than a lyophilized powder requiring routine reconstitution.
Is bacteriostatic water an established universal diluent? No. Available authoritative labeling does not establish bacteriostatic water as a universal diluent for arbitrary L-carnitine or levocarnitine powders.
Are formulation instructions specific? Yes. The labeled levocarnitine injection has specific compatibility information for parenteral dilution. This information should not be automatically transferred to a different L-carnitine salt, powder, research material or formulation.
What determines concentration? For a mathematical solution, concentration is determined by the amount of L-carnitine divided by the final solution volume.
Does the concentration calculation prove that a formulation is suitable? No. Mathematical concentration does not establish sterility, endotoxin control, chemical stability, compatibility or clinical suitability.
L-Carnitine Research Snapshot
These cards summarize the most important formulation and research considerations before examining concentration or dilution questions.
Diluent
Labeled levocarnitine injection compatibility includes 0.9% sodium chloride and Lactated Ringer's within specified concentration and storage conditions. This does not establish BAC water as a universal diluent.
Concentration
Concentration can be calculated mathematically from compound quantity and final volume. Formulation suitability requires separate evidence.
Quality
Identity, salt form, assay, impurities, material grade, sterility and endotoxin controls should be considered separately.
Clinical Evidence
Human studies have examined oral and intravenous L-carnitine in healthy volunteers and clinical populations, including patients receiving hemodialysis.
Regulatory Status
Levocarnitine has approved pharmaceutical formulations in the United States. Regulatory status should be distinguished from research powders and dietary supplements.
What Is L-Carnitine?
L-Carnitine, or levocarnitine, is the naturally occurring L-enantiomer of carnitine. It is a zwitterionic quaternary ammonium compound involved in cellular energy metabolism.
Carnitine participates in the transport of long-chain fatty-acyl groups into mitochondria, where fatty acids can undergo β-oxidation. This makes carnitine particularly important in tissues with substantial oxidative energy requirements.
L-carnitine should not automatically be treated as identical to acetyl-L-carnitine, propionyl-L-carnitine, L-carnitine tartrate or other carnitine derivatives. Their chemical forms, molecular weights, pharmacokinetics and research uses can differ.
How Does L-Carnitine Function Biologically?
Fatty-Acid Transport
The carnitine shuttle transfers long-chain fatty-acyl groups across the mitochondrial inner membrane system, enabling mitochondrial β-oxidation.
Energy Metabolism
Because of its role in fatty-acid transport, carnitine is closely associated with mitochondrial energy metabolism, particularly in tissues with high oxidative requirements.
Acyl-Group Homeostasis
Carnitine also participates in cellular management of acyl-CoA and acylcarnitine pools.
Renal Handling
Human pharmacokinetic research demonstrates substantial renal handling of carnitine. Renal function and hemodialysis can therefore materially affect circulating carnitine levels.
What Is L-Carnitine Being Studied For?
Primary Carnitine Deficiency
Levocarnitine is used therapeutically in documented carnitine deficiency states where replacement is clinically indicated.
Hemodialysis
Levocarnitine has been studied and used in patients receiving chronic hemodialysis because renal disease and dialysis can alter carnitine homeostasis.
Metabolic Research
Research has investigated carnitine availability, fatty-acid oxidation and metabolic physiology in different populations.
Exercise Research
L-carnitine has been extensively studied in exercise and performance research, although evidence for meaningful performance benefits varies by population, baseline status and study design.
Cardiometabolic Research
Researchers have investigated L-carnitine in cardiovascular and metabolic settings, with results depending strongly on the population and clinical endpoint.
Neurological Research
Acetyl-L-carnitine and other carnitine forms have also been investigated separately in neurological research. These findings should not automatically be attributed to L-carnitine itself.
Human Clinical Research
L-carnitine has a substantial human research history. Importantly, the route of administration and patient population strongly influence interpretation.
| Route | Research Context | Interpretation |
|---|---|---|
| Oral | Pharmacokinetics and metabolic research | Oral absorption is incomplete and dose-dependent. |
| Intravenous | Pharmacokinetic and clinical research | IV administration produces substantially different systemic exposure from oral administration. |
| Post-hemodialysis IV | Renal disease / dialysis-associated carnitine management | A labeled pharmaceutical use with specific dosing and monitoring requirements. |
Early pharmacokinetic research compared oral and intravenous L-carnitine in healthy subjects and found route-dependent disposition and relatively low oral bioavailability at the studied doses. :contentReference[oaicite:3]{index=3}
More recent randomized research has also compared oral and IV levocarnitine in maintenance-hemodialysis patients, illustrating why route-specific evidence should be kept separate. :contentReference[oaicite:4]{index=4}
Doses Studied in Clinical Research
Published studies have examined a wide range of L-carnitine quantities depending on the research question and population. These values describe research protocols and approved-label regimens; they are not individualized dosing recommendations.
| Research Setting | Example | Evidence Note |
|---|---|---|
| Healthy volunteers — IV | 20–60 mg/kg in pharmacokinetic research | Studied to characterize IV pharmacokinetics and safety. |
| Healthy volunteers — oral / IV | 2 g and 6 g research doses | Demonstrated route- and dose-dependent pharmacokinetic differences. |
| Hemodialysis | Label-supported dosing is weight- and clinical-status dependent | Requires clinical monitoring and should not be converted into generic research instructions. |
Important:
The purpose of this section is to summarize human research. Published clinical doses should not be interpreted as instructions for preparing or administering an unapproved L-carnitine product.
Routes Studied
Oral L-Carnitine
Oral L-carnitine has been studied extensively. Human pharmacokinetic research demonstrates incomplete absorption and dose-dependent systemic exposure.
Intravenous Levocarnitine
IV levocarnitine has been studied in healthy volunteers and clinical populations and is available as an approved sterile pharmaceutical formulation.
Other Carnitine Forms
Acetyl-L-carnitine and propionyl-L-carnitine have their own clinical and pharmacological literature. They should not be substituted for L-carnitine when interpreting research.
Research Formulations
A research powder, dietary supplement and approved injectable drug are different formulation categories and require separate quality and compatibility assessments.
L-Carnitine Reconstitution Research
L-Carnitine does not have a universal powder-reconstitution recipe.
This distinction is important because the FDA-labeled levocarnitine injection is supplied as a sterile solution, including a commonly labeled strength of 200 mg/mL.
Therefore, it would be scientifically incorrect to take a ready-to-use levocarnitine injection label and convert it into instructions for an arbitrary L-carnitine powder.
If a research material is supplied as a dry powder, the researcher should verify the exact chemical form, material grade, intended route, validated formulation instructions and specified diluent before preparing a solution.
L-Carnitine Diluent Considerations
The authoritative distinction is between compatibility data for a specific pharmaceutical formulation and a general claim that a particular diluent is suitable for all L-carnitine products.
| Question | Research Conclusion |
|---|---|
| Is BAC water a universal L-carnitine diluent? | Not established |
| Does labeled levocarnitine injection have compatibility data? | Yes |
| Label-supported parenteral solutions | 0.9% Sodium Chloride or Lactated Ringer's |
| Does that compatibility establish powder reconstitution? | No |
| Should formulation documentation control? | Yes |
Label-supported compatibility:
Current DailyMed labeling for levocarnitine injection states that the finished injection is compatible and stable when mixed in parenteral solutions of 0.9% sodium chloride or Lactated Ringer's at concentrations ranging from 0.5 mg/mL to 8 mg/mL, with storage at 25°C for up to 24 hours in PVC plastic bags.
This is compatibility information for the labeled levocarnitine injection. It is not a universal instruction to dissolve every L-carnitine powder in those solutions.
L-Carnitine Concentration Calculator
Concentration can be calculated mathematically from the amount of compound and the final solution volume.
Concentration (mg/mL) = Total L-Carnitine (mg) ÷ Final Volume (mL)
Mathematical example: A hypothetical solution containing 1,000 mg of L-carnitine in a final volume of 10 mL has a mathematical concentration of 100 mg/mL.
This calculation does not establish whether 100 mg/mL is an appropriate concentration for a particular formulation, administration route or research protocol.
Open Universal BAC Water Calculator
Important calculator limitation
The BacScience Universal BAC Water Calculator performs mathematical concentration and volume conversions. It does not determine chemical compatibility, sterility, endotoxin safety, stability, route suitability or an appropriate clinical diluent.
Labeled Levocarnitine Injection Concentration & Vial Quantity
Unlike many peptide products, an FDA-labeled levocarnitine injection is supplied as a finished sterile solution rather than as a powder that must routinely be reconstituted.
| Product characteristic | Labeled information | Interpretation |
|---|---|---|
| Strength | 200 mg/mL | Finished levocarnitine injection solution |
| Example vial | 1 g / 5 mL | 1,000 mg total levocarnitine |
| Larger labeled vial | 4 g / 20 mL | 4,000 mg total levocarnitine |
| Preservative | No preservative | Unused portion should be discarded according to labeling |
Current DailyMed listings describe levocarnitine injection at 200 mg/mL and include 1 g/5 mL single-dose vials; another current labeling entry also describes 4 g/20 mL single-dose vials. :contentReference[oaicite:5]{index=5}
L-Carnitine Stability & Storage Research
Finished Levocarnitine Injection
Current labeling states that the finished injection is compatible and stable when diluted in 0.9% sodium chloride or Lactated Ringer's within the specified concentration range and stored at 25°C for up to 24 hours in PVC bags.
Unspecified Research Powder
Stability data for one finished pharmaceutical formulation should not automatically be transferred to an unrelated dry L-carnitine material. Powder stability, reconstituted stability, container compatibility and storage conditions require formulation-specific evidence.
Storage distinction:
Current labeling for one levocarnitine injection product states controlled room-temperature storage of the unopened vial and advises avoiding excessive heat and freezing. The label also states that unused material from the opened single-dose vial should be discarded because the formulation contains no preservative.
Sterility & Endotoxin Considerations
A mathematical concentration calculation cannot establish that an L-carnitine preparation is sterile or nonpyrogenic.
Sterility
Injectable preparations require appropriate sterile manufacturing or validated sterile-compounding controls.
Endotoxin
Low chemical impurity levels do not by themselves demonstrate acceptable bacterial endotoxin control.
Material Grade
Dietary-supplement grade, analytical/research grade and pharmaceutical-grade materials should not be treated as interchangeable for sterile injectable use.
Container
Container-closure compatibility can affect stability, particulate control and product integrity.
Aseptic Preparation
If a sterile preparation is compounded, applicable sterile preparation standards and qualified procedures must be followed.
Traceability
Batch, lot, source, identity and analytical documentation should remain traceable.
L-Carnitine Quality & Purity Considerations
For research purposes, a certificate of analysis should be evaluated as part of a broader quality assessment rather than treated as proof of pharmaceutical suitability.
| Quality attribute | What to verify |
|---|---|
| Identity | Confirm L-carnitine / levocarnitine rather than a different carnitine derivative. |
| Salt / chemical form | Determine whether the material is free L-carnitine, hydrochloride, tartrate or another derivative. |
| Assay | Evaluate quantitative assay using an appropriate analytical method. |
| Impurities | Review relevant impurity and degradation information. |
| Sterility | Required for sterile injectable material and must be supported by appropriate controls. |
| Endotoxin | Route-specific endotoxin control is important for parenteral preparations. |
| Traceability | Lot number, source, documentation and test records should remain linked. |
Regulatory Status
Levocarnitine is an established pharmaceutical ingredient with approved drug formulations in the United States. Current DailyMed labeling describes levocarnitine injection as an Rx-only sterile pharmaceutical product.
This regulatory status should not be confused with every L-carnitine product sold as a dietary supplement or research material.
A research powder does not acquire the regulatory characteristics of an approved injectable merely because the active chemical is levocarnitine.
Safety Findings
- L-carnitine has extensive human exposure through oral and pharmaceutical formulations.
- Adverse effects depend on dose, route, formulation and patient characteristics.
- Gastrointestinal effects are among the commonly reported effects with oral supplementation.
- Patients with renal impairment may have altered carnitine disposition and require clinical monitoring when levocarnitine is used therapeutically.
- Injectable formulations introduce additional sterility, endotoxin, particulate and compounding-quality considerations.
- L-carnitine should not be confused with acetyl-L-carnitine or propionyl-L-carnitine when interpreting safety or efficacy data.
L-Carnitine Pharmacokinetic Research
Human pharmacokinetic studies demonstrate meaningful differences between oral and intravenous administration.
In one healthy-volunteer study, single 2 g and 6 g doses were evaluated by oral and intravenous routes. The investigators found dose-related elimination and substantially greater urinary recovery following IV administration than oral administration. :contentReference[oaicite:6]{index=6}
Another IV study evaluated 20, 40 and 60 mg/kg in healthy subjects and characterized plasma disposition using a multicompartment pharmacokinetic model. :contentReference[oaicite:7]{index=7}
Research interpretation:
Oral and injectable L-carnitine should not be treated as pharmacologically interchangeable simply because they contain the same active compound.
Research Limitations
- Research populations vary considerably.
- Different carnitine derivatives are frequently studied separately.
- Oral pharmacokinetics cannot automatically be applied to IV formulations.
- Compatibility data for an approved injection cannot establish the suitability of a research powder.
- Stability depends on concentration, formulation, container, temperature and storage duration.
- A COA does not by itself establish sterile injectable suitability.
- Mathematical concentration calculations do not establish clinical dosing.
Frequently Asked Questions
What is L-carnitine?
L-carnitine, also called levocarnitine, is the naturally occurring L-form of carnitine and participates in mitochondrial fatty-acid transport and energy metabolism.
Is L-carnitine the same as levocarnitine?
In pharmaceutical and biochemical contexts, levocarnitine refers to the biologically active L-isomer commonly called L-carnitine.
Does L-carnitine need to be reconstituted?
Not necessarily. An FDA-labeled levocarnitine injection is supplied as a ready-to-use sterile solution. A separate research powder may have different formulation requirements.
Can L-carnitine be reconstituted with BAC water?
BAC water should not be assumed to be a universal L-carnitine diluent. Compatibility must be established for the exact chemical form and formulation.
What diluents are documented for levocarnitine injection?
Current DailyMed labeling for levocarnitine injection documents compatibility with 0.9% sodium chloride and Lactated Ringer's within specified concentration and storage conditions.
Does that mean I can use those solutions with any L-carnitine powder?
No. Compatibility information for a labeled pharmaceutical injection should not automatically be transferred to an unrelated research powder or different formulation.
How do you calculate L-carnitine concentration?
Mathematical concentration in mg/mL equals the amount of L-carnitine in mg divided by the final solution volume in mL.
What is the concentration of a 1 g / 5 mL levocarnitine injection?
A 1 g amount in 5 mL corresponds mathematically to 200 mg/mL. This describes the labeled finished injection formulation and should not be interpreted as a powder reconstitution instruction.
Is L-carnitine the same as acetyl-L-carnitine?
No. Acetyl-L-carnitine is a distinct derivative with its own pharmacology and clinical literature.
Is L-carnitine the same as L-carnitine tartrate?
No. L-carnitine tartrate is a salt/formulation containing L-carnitine and tartaric acid and has a different molecular composition and molecular weight.
Does the BAC Water Calculator determine the correct L-carnitine diluent?
No. The calculator performs mathematical concentration conversions only. It does not establish chemical compatibility, sterility, endotoxin control, stability or clinical suitability.
Is L-carnitine clinically studied?
Yes. L-carnitine and levocarnitine have extensive human literature, including pharmacokinetic studies and clinical research involving carnitine deficiency and hemodialysis.
Calculate L-Carnitine Concentration
Use the BacScience Universal BAC Water Calculator for mathematical concentration and volume conversions. Always verify the formulation, chemical form, diluent and storage requirements independently.
Open BAC Water CalculatorRelated BacScience Research
BAC Water Calculator
Mathematical concentration and volume calculations.
Use the calculator →Sterile Research Materials
Learn how sterility, endotoxin and formulation quality affect research materials.
Explore research materials →Research Library
Explore additional BacScience research and formulation references.
Explore research →Scientific References
- DailyMed. Levocarnitine Injection, USP. Current labeling including concentration, compatibility, stability and storage information.
- PubMed. Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects.
- PubMed. Pharmacokinetics and safety of L-carnitine infused intravenously in healthy subjects.
- PubMed. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects.
- PubMed. Disposition and metabolite kinetics of oral L-carnitine in humans.
- PubMed. Efficacy of intravenous versus oral administration of levocarnitine in maintenance hemodialysis patients.
- PubChem. L-carnitine chemical identity and molecular information.
Last Reviewed
September 11, 2026
This page should be periodically reviewed as pharmaceutical labeling, clinical research, formulation data and regulatory information change.
Research information only. This page is provided for scientific and educational reference. It is not medical advice, prescribing guidance or a substitute for validated pharmaceutical formulation procedures. L-carnitine products differ in chemical form, grade, formulation, route and quality controls. Mathematical examples on this page should not be interpreted as instructions for human administration. Injectable preparations should be handled only within applicable professional, pharmaceutical and sterile-compounding requirements.